Does OxyVita, a New-Generation Hemoglobin-Based Oxygen Carrier, or Oxyglobin Acutely Interfere With Coagulation Compared With Normal Saline or 6% Hetastarch? An Ex Vivo Thromboelastography Study

OxyVita®C, a next-generation haemoglobin-based oxygen carrier, with coagulation capacity (OVCCC). Modified lyophilization/spray-drying process: proteins protection

“…Reconstitution (solubility) time of these powder forms of OxyVita V R C is 10-30 s in water ( Table 1). The liquid form of this polymer is currently in advanced pre-clinical studies at a number of independent laboratories as a dedicated oxygen delivery protein [9,10,[13][14][15].…”

“…This product is applicable when whole blood or RBCs are not available. OxyVita V R C, a new-generation haemoglobin-based oxygen carrier (HBOC) [8,9], is produced using a modified zero-linked polymerization process that employs chemical activators to incorporate cross-linked bovine haemoglobin tetramers into "super-polymeric" macromolecules. The liquid form of this HBOC is currently being studied in advanced pre-clinical studies [10].…”

“…Scientists at OXYVITA, Inc., have applied a unique protection process of the proteins with improved and modified lyophilization/spray-drying process to the product, in order to powderized OxyVita V R C. The process was proven to allow for molecular preservation of the HBOC and unchanged physiological activity of the product. This motivated us to apply the same technology in the lyophilization of other blood components (plasma and platelets) which are directly involved in coagulatory function [9]. This paper presents introductory results and efforts in working towards the development of a viable mixture of the above-mentioned products that includes components that are mutually compatible without alteration of their individual functions, exist in a powder form for ease of storage and transportation within a remote or combat environment and are able to be reconstituted in a physiological injectable (IV) fluid for immediate use.…”

Effects of Hemoglobin-Based Oxygen Carriers on Blood Coagulation

“…Dilutional coagulopathy is to be expected from a large fluid resuscitation with any fluid devoid of clotting factors or platelets, and so is not limited to HBOCs [12,13,21,28]. Studies have shown no increase in coagulopathy with HBOCs when compared to hetastarch fluids [2].…”

Haemoglobin-based oxygen carriers and myocardial infarction

“…In vitro experiments suggest that mixing human-based HBOCs with whole blood does not induce platelet aggregation or activation [46,47], but may enhance the response to certain agonists [48]. In contrast, bovine-based HBOCs may actually impair clot formation [49]. Ex vivo studies with blood after HBOC infusion into normal animals suggest that platelets are not activated and respond normally to agonists [50], but in rodent models of endothelial injury or thrombosis, human-based HBOCs caused a modest increase in platelet deposition [51] or more rapid thrombus occlusion [48].…”